The strategic partnership will also support the WHO resolution WHA78.13 with the aim to improve access to medical imaging and nuclear medicine

February 25, 2026 – Wiesbaden, Germany. The International Centers for Precision Oncology (ICPO) Foundation and the World Federation of Nuclear Medicine and Biology (WFNMB) have announced a partnership to expand access to precision oncology, particularly for patients in low- and middle-income countries. The partners seek to improve clinical standards, advance research, and enhance education for healthcare professionals through the QUANTALPHA Academy for Theranostics. This collaboration was signed at the WFNMB Congress in Cartagena, Colombia, in February 2026, during the satellite symposium about the “World Health Assembly Resolution WHA78.13 on Strengthening Medical Imaging Capacity”[1], organized by WFNMB and the International Atomic Energy Agency (IAEA). To address the global needs for medical imaging and nuclear medicine at a global level, the resolution was presented by Member States to achieve policy implementation through the World Health Organization (WHO) and its Global Diagnostics Coalition.